FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2626422015> ?p ?o ?g. }

• W2626422015 endingPage "627" @default.
• W2626422015 startingPage "627" @default.
• W2626422015 abstract "Abstract Background: In chronic myeloid leukemia (CML) the combination treatment of tyrosine kinase inhibitors (TKIs) with interferon-α (IFN-α) has proved to be effective and well-tolerated. IFN-α has long-term immunomodulatory effects, and when combined to TKI therapy, it may increase the success rates for treatment free remission. In our recent clinical trial NordCML007, a low-dose pegylated IFN-α was combined with dasatinib therapy. As dasatinib is also known to have immunostimulatory effects (activation of T and NK cells and downregulation of regulatory T cells), we aimed to monitor the immune effects of dasatinib and IFN-α combination treatment. Methods: 40 newly diagnosed CML patients participated in the NordCML007 clinical trial (NCT01725204). Patients were treated with 100 mg dasatinib QD and after 3 months IFN-α treatment was added (first 3 months 15 μg/week, then 25 μg/week of pegylated IFN-α). After 12 months of combination treatment, patients resumed to dasatinib monotherapy. In this immunological substudy, peripheral blood samples were collected at the diagnosis, 3, 12, and 24 months after the start of therapy. T- and NK-cells were phenotyped with multicolor flow cytometry, and their function (degranulation and cytokine secretion) was studied. In addition, a multiplexed cytokine and growth factor panel was performed (Proseek Multiplex Inflammation I96×96, Olink). Results: Dasatinib monotherapy led to an increase of NK-cell frequencies when compared to pre-treatment values (median diagnosis 6.8% vs. 3 months 12.8%, p<0.0001, Figure 1). In contrast, the proportion of B cells decreased (6.0% vs. 3.8%, p=0.001). Also moderate effects on the T cell subsets were observed (CD4+ 53% vs. 58%, p=0.02; CD8+ 47% vs. 43%, p=0.03). The more detailed immunophenotyping showed that at 3 months NK cells were more mature when compared to pre-treatment values. This could be observed as the increased proportion of CD16+ (86% vs. 77%, p=0.008) and CD57+ (79% vs. 67%, p=0.0001) NK cells. Correspondingly, the frequencies of CD56bright (median 3 months 3.9% vs. dg 6.1%, p<0.0001) and CD27+ (median 3 months 31.2% vs. dg 58.2%, p=0.004) NK cells decreased. The degranulation responses of NK cells when stimulated with K562 cells were also decreased (median 27.4% vs. 35.5% of CD56+ NK cells, p=0.02). Similar effects of dasatinib treatment were also observed within the T cell population, and at 3 months patients had more CD8+ terminally differentiated effector memory CD45RA+ (Temra) cells (22% vs. 32%, p=0.03). Correspondingly, both CD8+ and CD4+ effector memory (EM) populations decreased (CD8+ EM 34% vs. 24%, p=0.007; CD4+ EM 21 % vs. 14 %, p=0.0003). As observed with the NK cells, the degranulation and Th1 type cytokine secretion of T cells decreased during dasatinib treatment (CD107a/b+ 19.4% vs. 18.4% of CD8+ T cells, p=0.02; CD107a/b+ 12.7% vs. 8.8% of CD4+ T cells, p=0.005). Interestingly, 3 out of 4 patients who suffered from pleural effusion (PE) had exceptionally high CD57+CD8+ T cell frequencies (>70% of CD8+ T cells, median 38% in all patients) at diagnosis and during the treatment. The combination of IFN-α did not significantly affect the number of NK cells. Interestingly however, the addition of IFN-α treatment seemed to have an opposite effect on the NK cell phenotype than dasatinib treatment. The proportion of CD56bright NK cells increased (median 3 months 3.9% vs. 12 months 5.2%, p=0.03), and a decreasing trend was observed among CD16+ and CD57+ NK cells at 12 months. Similarly, the T cell surface markers shifted towards more immature phenotype (CD4+ EM 14% vs. 19%, p=0.002; CD4+ CM 36% vs. 28%, p=0.002; CD8+ Temra 32% vs. 17%, p=0.003) and the degranulation of CD4+ T cells and NK cells returned to the diagnosis level. The initiation of dasatinib treatment was associated with a decrease in several plasma protein concentrations (IL-18, IL-8, CXCL5, MCP-2, MCP-3, VEGF-A, CD244, LAP TGFβ1, TGFA, 4E-BP1, ADA, STAMPB, Casp8, OSM) and an increase in others (SCF, MCP-1). After IFN-α addition, the concentration of MCP-1 was further increased. Conclusions: These results show that dasatinib and IFN-α modulate both innate and adaptive immune systems. Interestingly, where dasatinib seems to induce a more mature immunophenotype, IFN-α counteracts this by driving a shift towards a more immature phenotype. Comparative analysis of the changes in the immunophenotype and function with the clinical outcome of the patients is ongoing. Disclosures Stentoft: Ariad: Research Funding; Pfizer: Research Funding; Novartis: Research Funding; Bristol-Myers-Squibb: Research Funding. Richter:Pfizer: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Ariad: Honoraria, Research Funding. Höglund:Akinion Pharmaceuticals: Consultancy; Janssen-Cilag: Honoraria. Mustjoki:Ariad: Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Novartis: Honoraria, Research Funding." @default.
• W2626422015 created "2017-06-23" @default.
• W2626422015 creator A5000071510 @default.
• W2626422015 creator A5000166823 @default.
• W2626422015 creator A5002063554 @default.
• W2626422015 creator A5004083002 @default.
• W2626422015 creator A5004612211 @default.
• W2626422015 creator A5005190962 @default.
• W2626422015 creator A5008868111 @default.
• W2626422015 creator A5010427139 @default.
• W2626422015 creator A5017932720 @default.
• W2626422015 creator A5030274890 @default.
• W2626422015 creator A5033314197 @default.
• W2626422015 creator A5044690676 @default.
• W2626422015 creator A5050873337 @default.
• W2626422015 creator A5051598887 @default.
• W2626422015 creator A5053646111 @default.
• W2626422015 creator A5055911435 @default.
• W2626422015 creator A5057088387 @default.
• W2626422015 creator A5057695659 @default.
• W2626422015 creator A5062230211 @default.
• W2626422015 creator A5062726602 @default.
• W2626422015 creator A5063447092 @default.
• W2626422015 date "2016-12-02" @default.
• W2626422015 modified "2023-10-15" @default.
• W2626422015 title "Effects of Dasatinib and Interferon-α Combination Treatment on the Immune System in CML" @default.
• W2626422015 doi "https://doi.org/10.1182/blood.v128.22.627.627" @default.
• W2626422015 hasPublicationYear "2016" @default.
• W2626422015 type Work @default.
• W2626422015 sameAs 2626422015 @default.
• W2626422015 citedByCount "0" @default.
• W2626422015 crossrefType "journal-article" @default.
• W2626422015 hasAuthorship W2626422015A5000071510 @default.
• W2626422015 hasAuthorship W2626422015A5000166823 @default.
• W2626422015 hasAuthorship W2626422015A5002063554 @default.
• W2626422015 hasAuthorship W2626422015A5004083002 @default.
• W2626422015 hasAuthorship W2626422015A5004612211 @default.
• W2626422015 hasAuthorship W2626422015A5005190962 @default.
• W2626422015 hasAuthorship W2626422015A5008868111 @default.
• W2626422015 hasAuthorship W2626422015A5010427139 @default.
• W2626422015 hasAuthorship W2626422015A5017932720 @default.
• W2626422015 hasAuthorship W2626422015A5030274890 @default.
• W2626422015 hasAuthorship W2626422015A5033314197 @default.
• W2626422015 hasAuthorship W2626422015A5044690676 @default.
• W2626422015 hasAuthorship W2626422015A5050873337 @default.
• W2626422015 hasAuthorship W2626422015A5051598887 @default.
• W2626422015 hasAuthorship W2626422015A5053646111 @default.
• W2626422015 hasAuthorship W2626422015A5055911435 @default.
• W2626422015 hasAuthorship W2626422015A5057088387 @default.
• W2626422015 hasAuthorship W2626422015A5057695659 @default.
• W2626422015 hasAuthorship W2626422015A5062230211 @default.
• W2626422015 hasAuthorship W2626422015A5062726602 @default.
• W2626422015 hasAuthorship W2626422015A5063447092 @default.
• W2626422015 hasBestOaLocation W26264220151 @default.
• W2626422015 hasConcept C126322002 @default.
• W2626422015 hasConcept C203014093 @default.
• W2626422015 hasConcept C2776178377 @default.
• W2626422015 hasConcept C2776999253 @default.
• W2626422015 hasConcept C2777583451 @default.
• W2626422015 hasConcept C2778690821 @default.
• W2626422015 hasConcept C2778729363 @default.
• W2626422015 hasConcept C2779536868 @default.
• W2626422015 hasConcept C3019892230 @default.
• W2626422015 hasConcept C71924100 @default.
• W2626422015 hasConcept C8891405 @default.
• W2626422015 hasConcept C90924648 @default.
• W2626422015 hasConcept C98274493 @default.
• W2626422015 hasConceptScore W2626422015C126322002 @default.
• W2626422015 hasConceptScore W2626422015C203014093 @default.
• W2626422015 hasConceptScore W2626422015C2776178377 @default.
• W2626422015 hasConceptScore W2626422015C2776999253 @default.
• W2626422015 hasConceptScore W2626422015C2777583451 @default.
• W2626422015 hasConceptScore W2626422015C2778690821 @default.
• W2626422015 hasConceptScore W2626422015C2778729363 @default.
• W2626422015 hasConceptScore W2626422015C2779536868 @default.
• W2626422015 hasConceptScore W2626422015C3019892230 @default.
• W2626422015 hasConceptScore W2626422015C71924100 @default.
• W2626422015 hasConceptScore W2626422015C8891405 @default.
• W2626422015 hasConceptScore W2626422015C90924648 @default.
• W2626422015 hasConceptScore W2626422015C98274493 @default.
• W2626422015 hasIssue "22" @default.
• W2626422015 hasLocation W26264220151 @default.
• W2626422015 hasOpenAccess W2626422015 @default.
• W2626422015 hasPrimaryLocation W26264220151 @default.
• W2626422015 hasRelatedWork W1510497893 @default.
• W2626422015 hasRelatedWork W1548870648 @default.
• W2626422015 hasRelatedWork W200163820 @default.
• W2626422015 hasRelatedWork W2015677102 @default.
• W2626422015 hasRelatedWork W2164748612 @default.
• W2626422015 hasRelatedWork W2333888998 @default.
• W2626422015 hasRelatedWork W2563198120 @default.
• W2626422015 hasRelatedWork W2566175026 @default.
• W2626422015 hasRelatedWork W4230849756 @default.
• W2626422015 hasRelatedWork W2072494396 @default.
• W2626422015 hasVolume "128" @default.
• W2626422015 isParatext "false" @default.
• W2626422015 isRetracted "false" @default.
• W2626422015 magId "2626422015" @default.

• next